Identifying Cancer-Specific Proteins Using Next-Gen Protein Sequencing

This case study details the application of Next-Gen Protein Sequencing™ (NGPS™) using Quantum-Si’s Platinum® technology at Sanavia Oncology. The company focuses on developing antibody therapeutics targeting novel cancer markers. The case study outlines the challenges faced in oncology, particularly the need to understand why some cancer patients do not respond to existing therapies. The integration of the Platinum instrument into the target identification workflow is discussed, highlighting its role in enhancing the characterization of cancer-specific proteins. The workflow involves parallel analyses using mass spectrometry and protein sequencing to validate promising targets. The case study also reflects on the positive experiences with the Platinum instrument, including installation and training support. Long-term goals include rapid characterization of cancer targets to improve therapeutic development, with an emphasis on the instrument's ability to provide detailed insights into protein variation. The study concludes with a vision for future advancements in protein sequencing technology.